Reckon will buy back the stake held by Intuit, severing ties with the direct competitor.
Brokers believe automotive parts distributor Burson is well placed to capitalise on opportunities.
Bell Potter initiates coverage on Mayne Pharma and takes a contrary stance to other brokers.
PS&C had to make its first downgrade to guidance since listing on ASX amidst generalised weakness in the IT sector.
CLSA learns Cover-More is protected against some of the pitfalls for travel insurers, changing tack on the stock. Bell Potter also initiates coverage with a Buy rating.
Baillieu Holst takes a look at the significant upside for Cellmid’s cancer targeting technology.
Virtus Health has made its first acquisition since listing, a 70% stake in an Irish IVF clinic.
Stem cell developer Cynata Technologies has found a fan in Baillieu Holst because of the potential to revolutionise regenerative medicine.
Thorn Group is showing signs of growth after flatlining in recent years but brokers are reserving judgement.
Select Harvests has been troubled by rainfall as it harvests the almond crop but strong prices provide an offset.